STOCK TITAN

[8-K] Johnson & Johnson Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Riscrivi il testo seguente:
Reescribe el siguiente texto:
다음 텍스트를 다시 작성하세요:
Réécrivez le texte suivant :
Schreibe den folgenden Text um:
Positive
  • None.
Negative
  • None.
Riscrivi il testo seguente:
Reescribe el siguiente texto:
다음 텍스트를 다시 작성하세요:
Réécrivez le texte suivant :
Schreibe den folgenden Text um:
0000200406false00002004062025-07-162025-07-160000200406us-gaap:CommonStockMember2025-07-162025-07-160000200406jnj:A1.150NotesDueNovember2028Member2025-07-162025-07-160000200406jnj:A2.700NotesDueFebruary2029Member2025-07-162025-07-160000200406jnj:A3.20NotesDueNovember2032Member2025-07-162025-07-160000200406jnj:A3.050NotesDueFebruary2033Member2025-07-162025-07-160000200406jnj:A1.650NotesDue2035Member2025-07-162025-07-160000200406jnj:A3.350NotesDueNovember2036Member2025-07-162025-07-160000200406jnj:A3.350NotesDueFebruary2037Member2025-07-162025-07-160000200406jnj:A3.550NotesDueNovember2044Member2025-07-162025-07-160000200406jnj:A3.600NotesDueFebruary2045Member2025-07-162025-07-160000200406jnj:A3.700NotesDueFebruary2055Member2025-07-162025-07-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): 
July 16, 2025
Johnson & Johnson
(Exact name of registrant as specified in its charter)
New Jersey1-321522-1024240
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933 
(Address of Principal Executive Offices)
 (Zip Code) 
Registrant's telephone number, including area code:
732-524-0400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, Par Value $1.00JNJNew York Stock Exchange
1.150% Notes Due November 2028JNJ28New York Stock Exchange
2.700% Notes due February 2029JNJ29BNew York Stock Exchange
3.200% Notes Due June 2032JNJ32New York Stock Exchange
3.050% Notes due February 2033JNJ33BNew York Stock Exchange
1.650% Notes Due May 2035JNJ35New York Stock Exchange
3.350% Notes Due June 2036JNJ36ANew York Stock Exchange
3.350% Notes due February 2037JNJ37BNew York Stock Exchange
3.550% Notes Due June 2044JNJ44New York Stock Exchange
3.600% Notes due February 2045JNJ45New York Stock Exchange
3.700% Notes due February 2055JNJ55New York Stock Exchange



Item 2.02 Results of operations and financial condition
On July 16, 2025, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the second quarter ended June 29, 2025.
Item 9.01 Financial statements and exhibits
(d)    Exhibits.
Exhibit No.Description of Exhibit
99.1
Press Release dated July 16, 2025 for the period ended June 29, 2025
99.2
Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fiscal second quarter and six months
104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.



Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:July 16, 2025
JOHNSON & JOHNSON
(Registrant)
By:
/s/ Robert J. Decker, Jr.
Robert J. Decker, Jr.
Controller
(Principal Accounting Officer)

FAQ

What information is available?

This document appears to contain limited substantive content.
Johnson & Johnson

NYSE:JNJ

JNJ Rankings

JNJ Latest News

JNJ Latest SEC Filings

JNJ Stock Data

376.02B
2.40B
0.06%
73.56%
0.96%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
NEW BRUNSWICK